Welcome to our dedicated page for Argenx Se news (Ticker: ARGX), a resource for investors and traders seeking the latest updates and insights on Argenx Se stock.
argenx SE reports developments as a global immunology company developing and commercializing antibody-based medicines for severe autoimmune diseases. Its updates center on VYVGART (efgartigimod alfa-fcab) and VYVGART Hytrulo (efgartigimod alfa and hyaluronidase-qvfc), including approved use in adult generalized myasthenia gravis and clinical and regulatory work across myasthenia gravis and chronic inflammatory demyelinating polyneuropathy.
Recurring announcements also cover product sales, business updates, presentations of neuromuscular data, and pipeline progress for candidates such as empasiprubart, a monoclonal antibody targeting complement factor C2, and adimanebart. Governance items include annual general meeting results, board appointments, and leadership transitions for the Euronext- and Nasdaq-listed foreign issuer.
argenx announced positive results from the Phase 3 ADVANCE trial of VYVGART (efgartigimod alfa-fcab) for adults with primary immune thrombocytopenia (ITP). The trial met its primary endpoint, showing a higher proportion of patients achieving sustained platelet response compared to placebo (21.8% vs. 5%, p=0.0316). Key secondary endpoints also demonstrated significant benefits. The safety profile of VYVGART was consistent with past trials. The ADVANCE-SC trial, which focuses on subcutaneous administration, is set to deliver topline data in Q1 2023.
argenx (ARGX) will participate in a fireside chat at the BofA Securities 2022 Healthcare Conference on May 11, 2022, at 10:40 a.m. P.T. in Las Vegas, NV. The event will be accessible via a live webcast on the company's Investors section of the argenx website, with a replay available for 90 days post-event. argenx aims to develop innovative antibody-based medicines for severe autoimmune diseases and is known for its pioneering work with the neonatal Fc receptor (FcRn) blocker.
argenx (Euronext & Nasdaq: ARGX) will host a conference call on May 5, 2022, at 2:30 pm CET (8:30 am ET) to discuss its Q1 2022 financial results and provide a business update. Investors can access the live audio webcast on the argenx website. A replay will be available for one year following the call.
Interim data from the ADAPT+ study show that long-term treatment with VYVGART leads to consistent improvements in disease scores for patients with generalized myasthenia gravis (gMG). The treatment demonstrated a favorable safety profile throughout multiple cycles. Conducted by argenx SE (ARGX), the ongoing Phase 3 study involved 139 patients, with an average treatment duration of 363 days. Results indicate repeatable efficacy and a low incidence of serious adverse effects, affirming VYVGART’s potential as a targeted therapy for gMG.
argenx SE (Euronext & Nasdaq: ARGX) announced interim data will be presented from the ADAPT+ study at the American Academy of Neurology Annual Meeting, April 2-7 in Seattle, WA. The ADAPT+ study evaluates the long-term safety, tolerability, and efficacy of VYVGART® (efgartigimod alfa-fcab) in adult patients with generalized myasthenia gravis (gMG). Key presentations include data on treatment burden and baseline characteristics from a pre-approval program. CEO Tim Van Hauwermeiren emphasized their commitment to improving outcomes for the gMG community.
argenx has announced that underwriters have fully exercised their option to purchase an additional 350,000 ordinary shares as part of a global offering, raising the total anticipated gross proceeds to approximately $805 million from 2,683,334 ordinary shares.
The offering, managed by J.P. Morgan and others, follows a filing with the SEC under an automatically effective shelf registration statement. This press release serves as informational and does not constitute an offer to sell securities.
argenx SE, a global immunology company, will hold its annual general meeting of shareholders on May 10, 2022, at Hilton Amsterdam Airport Schiphol. Important agenda items include re-appointments to the Board of Directors, discussion of the 2021 Annual Accounts, and an advisory vote on the 2021 remuneration report. Shareholders are encouraged to use electronic proxy voting. The full agenda and documents related to the meeting are available on the argenx website.
argenx SE has successfully completed a global offering, closing the sale of 2,333,334 ordinary shares for gross proceeds of approximately $700 million (around €637 million). The offering was managed by major financial institutions including J.P. Morgan and Morgan Stanley. The shares are listed on the regulated market of Euronext Brussels. This offering allows argenx to advance its pipeline of antibody-based medicines aimed at severe autoimmune diseases, bolstering its commitment to improving patient lives.
argenx SE has announced a global offering of ordinary shares, including American Depository Shares (ADSs), aimed at raising approximately $700 million (about €637 million). The offering includes 1,551,044 ADSs priced at $300 each and 782,290 ordinary shares at €273.10 each. The anticipated closing date is March 28, 2022, pending customary conditions. Additionally, underwriters have a 30-day option to purchase up to 350,000 shares. The offering is designed to support argenx's mission in treating severe autoimmune diseases.
argenx SE has initiated a global offering of $500 million in ordinary shares, potentially represented by American Depository Shares (ADSs). This offering includes a public offering in the U.S. and a private placement in Europe. The offering aims to close on a simultaneous basis. Additionally, underwriters may purchase up to 15% more shares. Notably, Baillie Gifford has expressed interest in acquiring up to $170 million of shares. The offering is overseen by J.P. Morgan, Morgan Stanley, Cowen, and SVB Leerink, with securities offered under a previously filed SEC registration statement.